Lynsey Teulings
Staff Affiliate - YNHHAbout
Titles
Staff Affiliate - YNHH
Education & Training
- MS
- University of Massachusetts Worcester , Graduate School of Nursing (2015)
- BA
- College of the Holy Cross, Biology (2010)
Research
Clinical Trials
Current Trials
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)
HIC ID2000033494RoleSub InvestigatorPrimary Completion Date05/31/2028Recruiting ParticipantsGenderBothAge18+ yearsA Window Trial of 5-Azacytidine or Nivolumab or Combination Nivolumab Plus 5-Azacytidine in Resectable HPV-Associated Head and Neck Squamous Cell Cancer
HIC ID2000025632RoleSub InvestigatorPrimary Completion Date09/30/2025Recruiting ParticipantsA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
HIC ID2000024768RoleSub InvestigatorPrimary Completion Date05/05/2025Recruiting ParticipantsGenderBothAge18+ yearsRadiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
HIC ID1311013073RoleSub InvestigatorPrimary Completion Date01/01/2027Recruiting ParticipantsGenderBothAge18+ years